Akero Therapeutics, Inc.
NASDAQ: AKRO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Cheng
- Employees
- 69
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $4.5B
- Website
- https://www.akerotx.com
Loading AKRO…
Loading profile data…Frequently asked questions about AKRO
What does Akero Therapeutics, Inc. (AKRO) do?
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational...
Where does AKRO trade?
Akero Therapeutics, Inc. (AKRO) trades on the NASDAQ Global Select.
What sector is AKRO in?
Akero Therapeutics, Inc. (AKRO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Akero Therapeutics, Inc.?
Andrew Cheng is the chief executive officer of Akero Therapeutics, Inc. (AKRO).
Where is Akero Therapeutics, Inc. headquartered?
Akero Therapeutics, Inc. is headquartered in United States.
Does AKRO pay a dividend?
Akero Therapeutics, Inc. (AKRO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AKRO go public?
Akero Therapeutics, Inc. (AKRO) completed its initial public offering in 2019.